Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in INNOVATIONS in Pharmacy from July 2016 to February 2017
Over the past 30 years, thousands of modeled cost-effectiveness studies have been published. Whether this effort has been worthwhile is debatable. For supporters of modeled cost-effectiveness studies, this effort has been worthwhile because the modeled claims are intended to inform health care decis...
Saved in:
Main Author: | Paul C Langley (Author) |
---|---|
Format: | Book |
Published: |
University of Minnesota Libraries Publishing,
2017-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims Published in Value in Health from January 2016 to December 2016
by: Paul C Langley, et al.
Published: (2017) -
Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure
by: Paul C Langley
Published: (2016) -
Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017) -
Imaginary Worlds: The Status of Simulation Modeling in Claims for Cost-Effectiveness In Diabetes Mellitus
by: Paul C Langley, et al.
Published: (2016) -
Imaginary Worlds: The Status of Modeled Quality Adjusted Life Year Claims for New Oral Anticoagulants in Atrial Fibrillation Published Between January 2012 and February 2016
by: Paul C Langley, et al.
Published: (2016)